S 50131 and S 51434 increase the hepatic triglyceride (TG) content without any effect on plasma free fatty acids (FFAs) after 4 days of daily oral treatment in db/db mice. (A,C), Hepatic TG content. (B,D), Plasma FFA levels. S 50131 (A,B) and S 51434 (C,D) were evaluated in independent experiments with GKA50 being used as positive control. All compounds were administered once daily at 130 μmol·kg−1, corresponding to 60.4 mg·kg−1 for GKA 50, 40.0 mg·kg−1 for S 50131 and 43.9 mg·kg−1 for S 51434. Data are means ± SEM of 10 animals. **P < 0.01, ***P < 0.001, significantly different from vehicle; Student's t-test.